Abstract

Hypertensive disorders of pregnancy (HDP) lead to the death of approximately 30,000 women annually, and the identification of biomarkers to predict their onset before symptom occurrence is crucial. Here, we aimed to identify the first-trimester maternal serum biomarkers for predicting early-onset HDP via a comprehensive metabolomic analysis. This study was conducted by the Fukushima Regional Center as an adjunct study to the Japan Environment and Children’s Study. The study comprised 12 patients with early-onset HDP and 12 control subjects with healthy pregnancy whose medical background information was matched with that of the patients by propensity-score matching. Capillary electrophoresis and mass spectrometry-based quantitative analysis of charged metabolites were performed with the first-trimester maternal serum samples. Welch’s t-test was used to analyse metabolite peak areas in the two groups. A total of 166 charged metabolites were identified. The peak area of N-dimethylglycine and S-methylcysteine was significantly higher in the first-trimester serum of patients with early-onset HDP than in the controls. Conversely, the peak area of munic acid was significantly decreased in the serum of patients with early-onset HDP. Although we identified potential biomarkers for the prediction and diagnosis of early-onset HDP, no clear marker was identified because of a low statistical power.

Highlights

  • Hypertensive disorders of pregnancy (HDP) lead to the death of approximately 30,000 women annually, and the identification of biomarkers to predict their onset before symptom occurrence is crucial

  • Among HDP, Eo-HDP occurs before 30 weeks in 0.3% of p­ atients[1], and it is associated with significant foetal mortality; the identification and treatment of women at a high risk of its development are a major challenge in modern obstetrics

  • As the controls were selected by propensity matching, there were no significant differences with regard to the maternal background

Read more

Summary

Introduction

Hypertensive disorders of pregnancy (HDP) lead to the death of approximately 30,000 women annually, and the identification of biomarkers to predict their onset before symptom occurrence is crucial. We aimed to identify the first-trimester maternal serum biomarkers for predicting early-onset HDP via a comprehensive metabolomic analysis. Among HDP, Eo-HDP occurs before 30 weeks in 0.3% of p­ atients[1], and it is associated with significant foetal mortality; the identification and treatment of women at a high risk of its development are a major challenge in modern obstetrics. Angiogenic factors, such as placental growth factor, vascular endothelial growth factor, soluble fms-related receptor tyrosine kinase 1, and ­endoglin[6] are potential biomarkers for Eo-HDP. Maternal background Gestational age at examination (weeks) Maternal age (years) Height before pregnancy (cm) Weight before pregnancy (kg) BMI before pregnancy (kg/cm2) Nulliparous, n (%) Systolic blood pressure in the first trimester (mmHg) Diastolic blood pressure in the first trimester (mmHg) HbA1c in the first trimester (mg/dL) Obstetrics outcomes Gestational age at delivery (weeks) Birth weight (g) SD of birth weight SGA, n (%) Weight of placenta (g)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call